Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers.
Age of Onset
Antibiotic Prophylaxis
Clinical Decision-Making
Disease Management
Disease Susceptibility
Female
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Infant
Infant, Newborn
Infection Control
Infections
/ diagnosis
Male
Neonatal Screening
Prognosis
Public Health Surveillance
Severe Combined Immunodeficiency
/ complications
Surveys and Questionnaires
Time-to-Treatment
Infections
hematopoietic stem cell transplant
newborn screening
primary immunodeficiency
prophylaxis
severe combined immunodeficiency
Journal
Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
22
05
2020
accepted:
07
09
2020
pubmed:
3
10
2020
medline:
15
1
2022
entrez:
2
10
2020
Statut:
ppublish
Résumé
The Primary Immune Deficiency Treatment Consortium (PIDTC) enrolled children with severe combined immunodeficiency (SCID) in a prospective natural history study of hematopoietic stem cell transplant (HSCT) outcomes over the last decade. Despite newborn screening (NBS) for SCID, infections occurred prior to HSCT. This study's objectives were to define the types and timing of infection prior to HSCT in patients diagnosed via NBS or by family history (FH) and to understand the breadth of strategies employed at PIDTC centers for infection prevention. We analyzed retrospective data on infections and pre-transplant management in patients with SCID diagnosed by NBS and/or FH and treated with HSCT between 2010 and 2014. PIDTC centers were surveyed in 2018 to understand their practices and protocols for pre-HSCT management. Infections were more common in patients diagnosed via NBS (55%) versus those diagnosed via FH (19%) (p = 0.012). Outpatient versus inpatient management did not impact infections (47% vs 35%, respectively; p = 0.423). There was no consensus among PIDTC survey respondents as to the best setting (inpatient vs outpatient) for pre-HSCT management. While isolation practices varied, immunoglobulin replacement and antimicrobial prophylaxis were more uniformly implemented. Infants with SCID diagnosed due to FH had lower rates of infection and proceeded to HSCT more quickly than did those diagnosed via NBS. Pre-HSCT management practices were highly variable between centers, although uses of prophylaxis and immunoglobulin support were more consistent. This study demonstrates a critical need for development of evidence-based guidelines for the pre-HSCT management of infants with SCID following an abnormal NBS. NCT01186913.
Identifiants
pubmed: 33006109
doi: 10.1007/s10875-020-00865-9
pii: 10.1007/s10875-020-00865-9
pmc: PMC8388237
mid: NIHMS1706629
doi:
Banques de données
ClinicalTrials.gov
['NCT01186913']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
38-50Subventions
Organisme : NCATS NIH HHS
ID : U01 TR001263
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States
Organisme : NIAID NIH HHS
ID : U54 AI082973
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL069294
Pays : United States
Organisme : NINDS NIH HHS
ID : U54 NS064808
Pays : United States
Organisme : NHLBI NIH HHS
ID : U10 HL069254
Pays : United States
Organisme : NIAID NIH HHS
ID : R13 AI094943
Pays : United States
Commentaires et corrections
Type : ErratumIn
Références
J Med Virol. 2009 Aug;81(8):1394-8
pubmed: 19551829
Blood. 2018 Oct 25;132(17):1737-1749
pubmed: 30154114
J Allergy Clin Immunol. 2017 Mar;139(3):733-742
pubmed: 28270365
J Allergy Clin Immunol. 2008 Dec;122(6):1087-96
pubmed: 18992926
J Clin Immunol. 2019 Nov;39(8):753-761
pubmed: 31432442
J Clin Immunol. 2013 Oct;33(7):1156-64
pubmed: 23818196
Blood Adv. 2017 Sep 05;1(20):1694-1698
pubmed: 29296816
J Allergy Clin Immunol. 2009 Dec;124(6):1152-60.e12
pubmed: 20004776
Blood. 2011 Mar 17;117(11):3243-6
pubmed: 21273302
Blood. 2013 Nov 28;122(23):3749-58
pubmed: 24113871
J Allergy Clin Immunol Pract. 2019 Nov - Dec;7(8):2863-2865.e3
pubmed: 31326381
J Allergy Clin Immunol. 2013 Jul;132(1):140-50
pubmed: 23810098
J Allergy Clin Immunol. 2012 Mar;129(3):622-7
pubmed: 22244594
Pediatrics. 2019 Feb;143(2):
pubmed: 30683812
N Engl J Med. 2015 Mar 5;372(10):933-43
pubmed: 25738669
Pediatrics. 2013 Jun;131(6):e1937-45
pubmed: 23713111
J Allergy Clin Immunol. 2014 Apr;133(4):1092-8
pubmed: 24290292
Clin Perinatol. 2012 Mar;39(1):69-81
pubmed: 22341538
N Engl J Med. 2014 Jul 31;371(5):434-46
pubmed: 25075835
Blood. 2017 Dec 21;130(25):2718-2727
pubmed: 29021228
Blood. 2002 Feb 1;99(3):872-8
pubmed: 11806989
JAMA. 2014 Aug 20;312(7):729-38
pubmed: 25138334